Ganx stock news
WebStock analysis for Gain Therapeutics Inc (GANX:NASDAQ GM) including stock price, stock chart, company news, key statistics, fundamentals and company profile. WebMar 13, 2024 · A rating of 89 puts Gain Therapeutics Inc near the top of the Healthcare sector according to InvestorsObserver.Gain Therapeutics Inc's score of 89 means that it ranks higher than 89% of stocks in the sector. In addition, its overall score of 73 ranks it higher than 73% of all stocks.
Ganx stock news
Did you know?
WebApr 5, 2024 · GANX Stock Overview. Gain Therapeutics, Inc., a biotechnology company, researches and develops novel therapies to treat diseases caused by protein misfolding in Switzerland and Spain. ... Recent News & Updates. Gain Therapeutics, Inc. Announces Executive Changes Dec 18. Consensus revenue estimates increase by 24% Nov 17. … WebMar 29, 2024 · Study results support the disease-modifying potential of structurally targeted allosteric regulators of GCase for the treatment of Alzheimer’s disease. BETHESDA, Md., March 29, 2024 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a biotechnology company leading the discovery and development of ...
Web1 day ago · Get the latest Gain Therapeutics, Inc GANX detailed stock quotes, stock data, Real-Time ECN, charts, stats and more. ... News for GANX. Zacks News; Earnings; Other News; Trades from $ 1. Price and ... WebApr 11, 2024 · Their GAN share price forecasts range from $2.00 to $6.50. On average, they predict the company's share price to reach $3.50 in the next year. This suggests a possible upside of 171.3% from the stock's current price. View analysts price targets for GAN or view top-rated stocks among Wall Street analysts.
WebGain Therapeutics, Inc. (GANX) delivered earnings and revenue surprises of -22.86% and 46.15%, respectively, for the quarter ended June 2024. Do the numbers hold clues to … WebGain Therapeutics, Inc. (GANX) Stock Charts . GANX Home; News; Ratings; Charts; Social; Price Target; Gain Therapeutics, Inc. (GANX): $4.72-0.07 (-1.46%) POWR …
WebMar 23, 2024 · March 23, 2024 - 4:05 pm. Company expects completion of IND-enabling studies of GT-02287 in H1 2024; Submission of dossier to start Phase 1 clinical trial of GT-02287 in GBA1 Parkinson’s Disease expected by mid-year 2024
Web2 days ago · GlobeNewswire. BETHESDA, Md., April 12, 2024 (GLOBE NEWSWIRE) — Gain Therapeutics, Inc. ( Nasdaq: GANX) (“Gain”, or the “Company”), a biotechnology company leading the discovery and development of allosteric small molecule therapies, today announced the appointment of C. Evan Ballantyne as the Company’s Chief … aries guardian angelWeb18 hours ago · Price To Free Cash Flow is a widely used stock evaluation measure. Find the latest Price To Free Cash Flow for Gain Therapeutics (GANX) balazs ekker dancing starsWebApr 8, 2024 · 5 brokerages have issued 12-month price objectives for Gain Therapeutics' stock. Their GANX share price forecasts range from $5.00 to $10.00. On average, they … aries ikawati arifahWeb$GANX Gain Therapeutics Appoints C. Evan Ballantyne as Chief Financial Officer. 12 Apr 2024 20:31:00 arie siswanto hukum persaingan usaha pdfWebFind the latest Gain Therapeutics, Inc. (GANX) stock quote, history, news and other vital information to help you with your stock trading and investing. balazs pinterWebMar 30, 2024 · Weaker technical forecast for Gain Therapeutics, Inc. as stock downgraded to Hold/Accumulate. (Updated on Mar 30, 2024) Buy or Hold candidate since 2024-03-13 Gain 14.04% PDF. The Gain Therapeutics, Inc. stock price fell by -2.28% on the last day (Thursday, 30th Mar 2024) from $4.82 to $4.71. During the last trading day the stock … balazuelaWebMar 24, 2024 · GANX Gain Therapeutics Inc Gain Therapeutics Reports Full Year 2024 Financial Results and Business Update Company expects completion of IND-enabling studies of GT-02287 in H1 2024Submission of dossier to start Phase 1 clinical trial of GT-02287 in GBA1 Parkinson's Disease expected by mid-year 2024$22.1 mi... aries ikawati arifah widya herbal indonesia